Treatment resistant depression - Articles

Top 10 Findings of Past Year: Treatment Resistant Depression and Benzos

October 14, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

We count down the top 10 research updates of the past year with a focus on treatment resistant depression and benzo withdrawal.

Expert Q&A

Ketamine-Assisted Therapy

June 1, 2024

Kyle T. Greenway, MD, MSc

Kyle T. Greenway, MD, MSc.

Assistant Professor of Psychiatry at McGill University. Director of the ketamine-assisted therapy program at Jewish General Hospital, Montreal, Canada.

Dr. Greenway has no financial relationships with companies related to this material.

A psychotherapeutic plan to make ketamine’s benefits last.

Research Update

Ketamine Fails to Outperform Placebo for Depression in Patients Under Anesthesia

May 1, 2024

Awais Aftab, MD.

Awais Aftab, MD. Dr. Aftab has no financial relationships with companies related to this material.

A look whether administering ketamine during general anesthesia changes its ability to treat depression.

Expert Q&A

Ketamine Use and Misuse

April 1, 2024

Keith A. Trujillo, PhD

Keith A. Trujillo, PhD.

Emeritus Professor of Psychology, California State University, San Marcos, CA.

Dr. Trujillo has no financial relationships with companies related to this material.

Ketamine and esketamine represent some of the most powerful rapid-acting agents in our armamentarium of treatments for depression. However, ketamine is also an addictive substance, and there is emerging evidence that the widespread use of ketamine may be causing more patient harms than we were previously aware of. Here, Dr. Trujillo discusses how to use ketamine safely in clinical practice.

EXPERT Q&A

Understanding TMS: A Primer for Therapists

February 26, 2024

Faizi Ahmed MD

Faizi Ahmed MD. Affiliate Assistant Professor of Psychiatry and Behavioral Neurosciences at the University of South Florida; private practice at The Neuropsychiatry and TMS Group, Tampa, Florida.

Dr. Ahmed has no financial relationships with companies related to this material.

The relevance of transcranial magnetic stimulation for therapists - what they should know about its mechanism, clinical applications, and emerging research.

CARLAT WEBINAR

Ketamine and the Evolving Psychopharmacologic Pipeline for Depression

December 8, 2023

Robert C. Meisner, MD

Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians.

Clinical Update

Lithium for Children and Adolescents

November 2, 2023

Max S. Rosen, MD

Max S. Rosen, MD. Assistant Professor of Psychiatry (Child); Director, Child & Adolescent Psychiatry Outpatient Services; Washington University School of Medicine, St. Louis, MO.

Dr. Rosen has no financial relationships with companies related to this material.

Lithium is FDA-approved for bipolar disorder in children and adolescents 12 years and up; however, its potential off-label utility is broad, from affective aggression to anorexia nervosa. This clinical update covers how to prescribe lithium for children and adolescents and how to talk with patients and parents about lithium.

Bipolar Treatment Upgrade Part I

July 10, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

Updates from the 2023 International Bipolar Conference, including new diagnostic tools for bipolar disorder. Stanford researchers propose a new subtype of depression.

Stahl Goes Generic: 3 Reasons to use MAOIs

June 12, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

Stephen Stahl steps down from the industry-sponsored podium to remind us of 3 reasons to use an MAOI: Atypical depression, treatment-resistant depression, and social anxiety disorder.

Research Update